Christine Childrose’s human resources career has taken her from General Electric and Albany Molecular Research Inc. to Regeneron Pharmaceuticals, one of the region’s fastest-growing companies. Credit: bizjournals - Published
Political uncertainty and trade tensions with China have prompted many businesses to take a conservative cash position in recent months, bucking predictions that last year's tax-reform law would spur.. Credit: bizjournals - Published
In early trading on Friday, shares of Regeneron Pharmaceuticals topped the list of the day's best performing components of the Nasdaq 100 index, trading up 1.6%. Year to date, Regeneron Pharmaceuticals..
In early trading on Monday, shares of Kraft Heinz (KHC) topped the list of the day's best performing components of the Nasdaq 100 index, trading up 2.2%. Year to date, Kraft Heinz has lost about 33.3%..
Shares of Bluebird Bio (NASDAQ:BLUE) slipped Monday in the wake of the unveiling of new data which evaluated the company’s LentiGlobin gene therapy in patients with both transfusion-dependent.. Credit: Proactive Investors - Published
U.K. Biobank, a huge collection of patients’ health and genetic information, is expected to attract as much as $320 million in investment as Britain tries to bolster its life-sciences sector with.. Credit: SFGate - Published
Inovio Pharmaceuticals Inc (NASDAQ:INO) topped earnings expectations in its third-quarter results as research and development expenses decreased. The biotech reported a net loss of $0.27 per share on.. Credit: Proactive Investors - Published
Program designed to help millions of affected patients and caregivers better understand and manage this skin condition
BOSTON (PRWEB) November 07, 2018
The Asthma and Allergy Foundation of.. Credit: PRWeb - Published
Regeneron Pharmaceuticals Inc's (NASDAQ:REGN) third-quarter results topped both their earnings and revenue forecasts on stronger sales of their medical products, with shares getting a modest boost in.. Credit: Proactive Investors - Published
Clearside Biomedical Inc (NASDAQ:CLSD) shares tanked after its Phase 3 clinical trial didn’t go according to plan. Shares of the Georgia-based biopharma fell nearly 50% to $2.90 in Monday pre-market.. Credit: Proactive Investors - Published
Adverum Biotechnologies Inc (NASDAQ:ADVM) shares tumbled on Friday after the company announced it will not continue development of a gene therapy program to treat A1AT for liver or lung disease. "While.. Credit: Proactive Investors - Published